Lay review is an essential step in the plain language summary (PLS) writing process. The reason being that it is extremely important that the PLS, or lay summary, is written in a patient-friendly, easy-to-understand style. Lay reviews also provide the medical writer with invaluable information to ensure that the document meets these standards.

Generally, lay reviewers are those with a non-science background. However, it is vital that lay reviewers are trained to know what to look for. When getting started, lay reviewers should ask themselves these questions while reviewing a plain language summary:

  • Is the following addressed: Who, What, Where, When, Why, How?
  • Is the text ordered logically and not redundant?
  • Is the main purpose of the study obvious at first reading?
  • Are short sentences used?
  • Is the text appropriately broken up in paragraphs or bullet points?
  • Are everyday English words used instead of complex language?
  • Are complicated medical terms defined at first use?
  • Are simple verbs used, such as “buy” instead of “purchase”?
  • Are the timing of events clearly defined?
  • Is the text is non-promotional, including no suggestion of efficacy, safety, or intended use, or no persuasive wording to emphasize safety or efficacy?
  • Are graphics easy to read and understand?
  • Are graphics consistent with the message in the text?
  • Can all graphics be understood on their own, without having to read the text?

Key Issue: Avoiding Promotional Language

It is vital that lay summaries remain as neutral, non-promotional documents. The lay reviewer should check that any language used in the PLS is not promotional; this is an essential aspect of the lay review process.

Recognizing promotional vs. non-promotional language may be difficult at first. Here are a few examples:

plain language summary lay summaries Avoiding Promotional Language cro services vendor mms holdings experts example

Click to view an expertly-crafted lay summary template

Suggested For You

perspectives

May 29th, 2024

Confined Deferrals in Clinical Trial Applications: Anticipating the Revised EU CTR Transparency Rules

perspectives

November 7th, 2023

Plain Language Protocol Synopsis – Meeting the EU Regulation

perspectives

October 13th, 2023

EMA Revised Transparency Rules Eliminate the Deferral Mechanism for Clinical Trial Data Publication

perspectives

October 3rd, 2023

Plain Language Summary of Publications: A Key Step To Build Transparency With The Patient Community

perspectives

September 6th, 2023

Relaunch of EMA Policy 0070 in September 2023: The European Medicines Agency’s Revived Commitment to Transparency

perspectives

June 28th, 2023

EMA Policy 0070: Much Awaited Revamp for Clinical Trial Transparency

perspectives

November 30th, 2022

A Step-by-Step Approach to Determining Company Confidential Information (CCI) in Redaction Proposal Packages

perspectives

September 15th, 2022

How does the European Union Clinical Trial Information System (EU-CTIS) Affect Clinical Trial Transparency?

perspectives

July 29th, 2022

Clinical Trial Disclosures 101: The Basics You Need to Know

perspectives

March 31st, 2022

How to Solve Challenges in Plain Language Summary Writing

perspectives

July 16th, 2021

Attention Sponsors, Be Prepared to Publish Your Interim Clinical Study Results

perspectives

May 27th, 2021

EU Clinical Trials Regulation: The Need for Coordination by Sponsors